Pharmaceuticals Australia

Australia Severe Asthma Biologics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Australia Severe Asthma Biologics Market Industry Trends and Forecast to 2034: Segmented by (Target, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $170.2 Mn Placeholder estimate
Estimate 2025 $190.1 Mn 1.3% of the global market
Projected 2034 $514.7 Mn 170.7% Adds $324.6 Mn over 9 forecast years
CAGR 2025–2034 11.7% Faster than 61% of 180 Pharmaceuticals markets here
Key players 5
  • Australia is 1.31% of the global market.
  • In APAC, the largest is China at $1.33 Bn.
  • Fastest growing: India at 13% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$324.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Severe Asthma Biologics Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $170.2 Mn — —
2025 (base) $190.1 Mn +$19.9 Mn —
2026 (forecast) $212.4 Mn +$22.2 Mn +11.7%
2027 (forecast) $237.2 Mn +$24.9 Mn +24.8%
2028 (forecast) $265.0 Mn +$27.8 Mn +39.4%
2029 (forecast) $296.0 Mn +$31.0 Mn +55.7%
2030 (forecast) $330.6 Mn +$34.6 Mn +73.9%
2031 (forecast) $369.3 Mn +$38.7 Mn +94.2%
2032 (forecast) $412.5 Mn +$43.2 Mn +117%
2033 (forecast) $460.8 Mn +$48.3 Mn +142.3%
2034 (forecast) $514.7 Mn +$53.9 Mn +170.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Severe Asthma Biologics Market Analysis at a glance
Market size, 2025$190.1 Mn placeholder estimate
Forecast, 2034$514.7 Mn placeholder estimate
Growth (CAGR), 2025–203411.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledAsthma Biologics
SegmentsTarget, age and end user (see all)
Key playersSanofi, Regeneron Pharmaceuticals, AstraZeneca, GSK PLC, Novartis AG (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
Active clinical trials4 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Severe Asthma Biologics Market Analysis Executive Summary

Severe asthma biologics are injections that block immune signals driving severe asthma attacks.

Key segments of the severe Asthma Biologics market include target (IL-5, IL-4/IL-13 and IgE) and age (Children and Adults).

Bar chart: Australia Severe Asthma Biologics market size, 2024–2034, placeholder estimates. $170.2 Mn in 2024, $190.1 Mn in 2025 and $514.7 Mn in 2034, 11.7% CAGR.
Australia Severe Asthma Biologics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Severe Asthma Biologics Market Dynamics

Market Growth Drivers

Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the severe Asthma Biologics market.

Opportunity

Earlier screening, new drug classes and home-based care give the severe Asthma Biologics market room to grow.

Market Restraints

Late diagnosis, high prices of new medicines, limited specialist care and poor adherence hold back the severe Asthma Biologics market.

Competitive Landscape for Severe Asthma Biologics Market in Australia

The severe Asthma Biologics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Severe Asthma Biologics Market in Australia

Severe Asthma Biologics in Australia: rules, payment and research

Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2] ClinicalTrials.gov lists 4 studies on Severe Asthma Biologics that are recruiting, active or about to start in Australia.⁠[3]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for severe Asthma Biologics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Severe Asthma Biologics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Severe Asthma Biologics in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Severe Asthma Biologics market in Australia?
Placeholder estimate: about $190.1 Mn in 2025, rising to about $514.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Severe Asthma Biologics market in Australia growing?
Placeholder estimate: about 11.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Severe Asthma Biologics market report cover?
The report splits the market by target (IL-5, IL-4/IL-13, IgE, TSLP), age (Children, Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Severe Asthma Biologics market?
Key players include Sanofi, Regeneron Pharmaceuticals, AstraZeneca, GSK PLC and Novartis AG.
What is driving the Severe Asthma Biologics market?
Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the severe Asthma Biologics market.
Who regulates Severe Asthma Biologics in Australia?
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Severe Asthma Biologics are running in Australia?
4 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
How much research is published on Severe Asthma Biologics?
PubMed lists 322 papers on Severe Asthma Biologics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Australia

See all

Related on respiratory and biologics and biosimilars

See the topic